Fluticasone Propionate

Transaction adds TYMLOS ® to portfolio alongside NUZYRA ® and XHANCE ® and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026 KING OF PRUSSIA, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic areas, today announced the completion of its combination with Radius Health, Inc., adding the osteoporosis therapy TYMLOS ® (abaloparatide) to its growing commercial portfolio of differentiated specialty medicines. Paratek is a specialty pharmaceutical platform company with a portfolio of diverse, innovative medicines well positioned for long-term growth. The company integrates and advances assets through disciplined commercial execution, lifecycle management, and clinical development, with a proven track record of integrating and growing pharmaceutical assets across multiple therapeutic areas. The transaction, which closed this week, brings together two complementary organizations backed by B-FLEXION Life Sciences, and further advances Paratek’s growth strategy of building a pharmaceutical platform in high-need, targeted therapeutic areas. The combined company is expected to generate nearly $1 billion in revenue in 2026, reflecting the scale and breadth of Paratek’s platform. “Today marks an important milestone for both Paratek and Radius,” said Evan Loh, M.D., Chief Executive Officer of Paratek. “Radius has built an impressive organization under the leadership of CEO Scott Briggs and its dedicated and talented team, and we look forward to building on that strong foundation together as we enter this next chapter. With our combined expertise in serving specialists and patients with significant, focused medical needs, we are well positioned to expand the impact of our medicines and continue delivering meaningful therapies to the patients and communities who rely on us.” Nithya Desikan, Operating Partner at B-FLEXION Life Sciences and Chair of the Board of Paratek, said: “We couldn’t be more pleased about the combination of these two companies and are committed to investing and building on their remarkable track records. With its scientific and commercial excellence and unwavering commitment to improving the lives of patients, Radius has done outstanding and innovative work establishing TYMLOS as an important therapy for osteoporosis. Paratek has a similarly strong track record of commercial and operational excellence, including successfully integrating targeted pharmaceutical assets. By bringing these organizations together, we are confident that Paratek is poised to accelerate growth for its expanding platform of innovative medicines that address significant patient needs.” With the completion of this transaction, Paratek’s portfolio will span infectious disease, podiatry, otolaryngology, allergy, rheumatology, endocrinology, and gynecology, supported by experienced medical, commercial, and operational teams with deep expertise in serving specialist physicians and patients with significant medical needs. The transaction adds TYMLOS to Paratek’s portfolio alongside NUZYRA ® (omadacycline), a once-daily antibiotic therapy for serious community-acquired infections, including complicated skin infections and pneumonia; and XHANCE ® (fluticasone propionate), a treatment for chronic rhinosinusitis with or without nasal polyps. “We are thrilled to announce the successful closing of this combination, which represents another significant achievement for the B-FLEXION Life Sciences platform,” said Peter Agnes, Operating Partner at B-FLEXION Life Sciences. “Our strategy has been to build a diversified life sciences platform anchored by high-quality, durable assets with meaningful impact for patients. This combination reflects that long-term commitment. We remain focused on identifying and acquiring additional important products that complement our platform and drive sustainable, long-term value creation. We have immense conviction in the potential and future success of Paratek as it enters this next phase of growth.” B-FLEXION Life Sciences acquired Paratek in 2023 and has since positioned the company as a platform for building a diversified specialty portfolio. The transaction was financed with capital from B-FLEXION Life Sciences and debt financing from funds managed by Blackstone Credit & Insurance; Sixth Street; Oaktree Capital Management, L.P.; Silver Point Capital; and Pharmakon Advisors, LP, with Wilmington Trust, National Association, serving as administrative agent. Lazard acted as the exclusive financial advisor to B-FLEXION Life Sciences and Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to B-FLEXION Life Sciences and Paratek Pharmaceuticals. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a specialty pharmaceutical company with a portfolio of differentiated medicines serving patients across multiple therapeutic areas. The company integrates and advances commercial-stage assets through disciplined commercial execution, lifecycle management, and clinical development initiatives designed to expand and strengthen its portfolio. Paratek’s products include NUZYRA ® (omadacycline), XHANCE ® (fluticasone propionate), and TYMLOS ® (abaloparatide). Paratek is privately held by B-FLEXION Life Sciences. For more information, visit or follow us on LinkedIn and X . About B-FLEXION Life Sciences B-FLEXION Life Sciences is an investment manager and part of the wider B-FLEXION group, the private, entrepreneurial investment firm that has offices across Europe and the United States and which seeds, acquires and builds investment partnerships across a number of focused fields. Through B-FLEXION Life Sciences it also makes principal investments in operating businesses across biotech, therapeutics, diagnostics, physician practice management, and more. It is an active owner, applying the experience and skills of its investment and operations team to work closely with management at its portfolio companies with the shared goals of bringing safe and effective treatments to market while also moving towards and through key value inflection points. MEDIA CONTACT: Adam Silverstein adam@scientpr.com

A report from Sen. Maggie Hassan, D-N.H., describes how GSK avoided paying $385 million in Medicaid rebates and retained its monopoly of the market for asthma inhaler Flovent. More than 20 years after gaining FDA approval for Flovent, GSK still controlled the market in the U.S. for the asthma inhaler through a partnership with an “authorized generic” dealer, a setup that forced many users to pay higher prices and allowed the British drugmaker to avoid paying Medicaid rebates, according to a report (PDF) released by Sen. Maggie Hassan, D-N.H.GSK’s control of the market reduced access to Flovent and created financial hardships for some who needed the medicine, according to the report. The result was worsening symptoms for patients in need and more emergency room visits and hospitalizations, the report added.“For decades, (GSK) has blocked competitors and increased prices on a life-saving asthma inhaler to unconscionable levels, with children, families and taxpayers paying the price,” Hassan said in a statement. “Congress must act to close the loopholes that GSK exploited so that no other Big Pharma company can cause the harm that GSK did.”In 2024, GSK exploited a loophole in the American Rescue Plan Act, which President Joe Biden signed into law in 2021 and went into effect in 2024, according to the report. The law required drugmakers that raised prices for drugs higher than the rate of inflation in previous years to make a rebate payment to Medicaid. But, by taking branded Flovent off the market at the start of 2024, GSK freed itself from the liability and saved an estimated $368 million in 2024 alone, according to Hassan’s report. Before the law went into effect, GSK had already struck a deal with Ohio-based Prasco Laboratories, allowing it to sell Flovent as an authorized generic. Even though the product was sold by Prasco at a discount to the branded version of Flovent, it ended up costing patients more because they could no longer take advantage of previous rebates and discounts that were offered by GSK. Without these deals, insurers and pharmacy benefit managers denied or delayed coverage of the authorized generic, making it more expensive for patients and creating an access problem for those who needed the treatment.Earlier this month, Glenmark scored FDA approval for its generic version of Flovent. At the time, pharmacy media outfit rxradio.fm hailed the nod as the “first true generic” for the treatment, “potentially reshaping access and pricing for millions of asthma patients.” The Glenmark approval came two years after congressional leaders began pressuring GSK to surrender its “monopoly protection.”“No company should be able to game the system the way GSK did,” Hassan added during a media briefing Monday.For its part, GSK said that when Prasco launched the authorized generic in May 2022, the product’s wholesale acquisition cost was 35% below that of branded Flovent.   “From the beginning, we took steps to ensure that the transition from branded Flovent to the AG would not jeopardize patient access,” a GSK spokesperson said in an email. “We started notifying payors of the transition to the AG at the beginning of 2023. In mid-2023, we informed the [FDA], which in turn provided public notification of the discontinuation of branded Flovent on its website. Our sales team sent emails and letters notifying Flovent prescribers of the transition. Over the course of months, we carried out an expansive communications plan to also convey the information to wholesalers, distributors, pharmacists, and patients.” GSK added that “external factors” have impacted patient access to the authorized generic and that it is not involved in the “process of negotiating or deciding formulary coverage, rebates or final net price.” The company also said it has supported Prasco’s launch of a patient assistance program for the authorized generic, which provides free products to patients who can’t afford treatment.According to Hassan’s report, information investigators received from three PBMs indicated that the net cost to plan sponsors for an average beneficiary using the authorized generic versions of Flovent was nearly five times higher than the cost for branded Flovent. This indicates that while the authorized generic’s list price was lower than that of the branded medicine, the lack of other rebates or discounts made the substitute more expensive. A survey of clinicians indicated that 37% said the discontinuation of Flovent had a moderate impact on their practice and 56% said it had a severe impact, according to the report. One PBM tied the discontinuation of Flovent to a 20% decrease in the use of inhaled corticosteroids by its beneficiaries.In 2022, GSK was accused in a class-action lawsuit of using a ploy known as “device hopping,” in which a branded inhaler is retired and succeeded by a follow-on inhaler with the same active ingredients. The new product then gets a new patent and regulatory protection periods, keeping generic competition at bay.